Skip to content

Concert Pharmaceuticals (NASDAQ: CNCE), founded in 2006, is a publicly-traded, clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that can be improved with deuterium substitution to enhance clinical safety, tolerability, and efficacy. Concert raised an $84M IPO in 2014.

Latest News from Concert Pharmaceuticals